Anne M. Traynor

Internal Medicine

600 Highland Ave
Madison, WI 53792

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer.

Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer.

Journal: Clinical lung cancer

Published: January 22, 2024

A retrospective cohort study of the anesthetic management of postpartum tubal ligation.

A retrospective cohort study of the anesthetic management of postpartum tubal ligation.

Journal: International journal of obstetric anesthesia

Published: August 10, 2023

Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b Trial.

Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b Trial.

Journal: International journal of radiation oncology, biology, physics

Published: June 06, 2023

An analysis of emerging food safety and fraud risks of novel insect proteins within complex supply chains.

An analysis of emerging food safety and fraud risks of novel insect proteins within complex supply chains.

Journal: NPJ science of food

Published: May 20, 2023

A survey of United States obstetric anesthesiologists' perceived value of obstetric anesthesiology fellowship.

A survey of United States obstetric anesthesiologists' perceived value of obstetric anesthesiology fellowship.

Journal: International journal of obstetric anesthesia

Published: April 01, 2023

MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.

MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: December 07, 2022

Corrigendum: Myosteatosis as a Shared Biomarker for Sarcopenia and Cachexia Using MRI and Ultrasound.

Corrigendum: Myosteatosis as a Shared Biomarker for Sarcopenia and Cachexia Using MRI and Ultrasound.

Journal: Frontiers in rehabilitation sciences

Published: June 30, 2022

A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.

A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.

Journal: Cancer

Published: April 26, 2022

Myosteatosis as a Shared Biomarker for Sarcopenia and Cachexia Using MRI and Ultrasound.

Myosteatosis as a Shared Biomarker for Sarcopenia and Cachexia Using MRI and Ultrasound.

Journal: Frontiers in rehabilitation sciences

Published: March 14, 2022

An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.

An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.

Journal: Thyroid : official journal of the American Thyroid Association

Published: June 16, 2020

Overcoming Barriers: Evidence-Based Strategies to Increase Enrollment of Underrepresented Populations in Cancer Therapeutic Clinical Trials-a Narrative Review.

Overcoming Barriers: Evidence-Based Strategies to Increase Enrollment of Underrepresented Populations in Cancer Therapeutic Clinical Trials-a Narrative Review.

Journal: Journal of cancer education : the official journal of the American Association for Cancer Education

Published: November 13, 2019

Quantitative FDG PET/CT may help risk-stratify early-stage non-small cell lung cancer patients at risk for recurrence following anatomic resection.

Quantitative FDG PET/CT may help risk-stratify early-stage non-small cell lung cancer patients at risk for recurrence following anatomic resection.

Journal: Journal of thoracic disease

Published: June 11, 2019

Showing 1-12 of 56

Last Updated: 09/26/2026